科伦药业(002422.SZ)：罗替高汀贴片获药品注册批准

Core Viewpoint - Kelong Pharmaceutical has received approval from the National Medical Products Administration for its chemical drug "Rotigotine Patch," indicating a significant advancement in its product portfolio and potential market opportunities in the treatment of Parkinson's disease [1] Company Summary - Kelong Pharmaceutical (002422.SZ) announced the registration approval of "Rotigotine Patch" [1] - The drug was developed by UCB Pharma and was first approved in the European Union in 2006 [1] - The drug was imported and approved for use in China in 2018 [1] Industry Summary - "Rotigotine Patch" is indicated for the treatment of early idiopathic Parkinson's disease symptoms and can be used as monotherapy or in combination with Levodopa throughout various stages of the disease [1]